Expression of 20 alpha-hydroxysteroid dehydrogenase in nonlymphoid hemopoietic cell lines

European Journal of Immunology
J M GarlandT M Dexter

Abstract

Expression of 20 alpha-hydroxysteroid dehydrogenase (20 alpha-SDH), a putative T cell marker, has been examined in a number of nonlymphoid hemopoietic cell lines. Both promyelocytic and stromal bone marrow lines expressed significant 20 alpha-SDH activity which was not correlated with virus infection or growth rate. 20 alpha-SDH therefore is not a unique marker for T cells in hemopoietic tissues. This result is discussed in relationship to the action of the newly proposed interleukin 3.

References

Oct 1, 1980·The Journal of Experimental Medicine·T M DexterD Metcalf

❮ Previous
Next ❯

Citations

Nov 1, 1994·Immunology Today·P W KincadeD C Scott
Mar 28, 1998·Leukemia & Lymphoma·A MiadonnaG Lambertenghi Deliliers
Oct 1, 1983·Immunology Today·J D Watson, R L Prestidge
Feb 1, 1994·Immunological Reviews·P W KincadeG Smithson
Nov 1, 1983·The Journal of Pathology·T M Dexter, T D Allen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.